Evaluation of Safety and Efficacy of Using Imagine™ Computerized Radiofrequency System for Skin Tightening
1 other identifier
interventional
30
1 country
1
Brief Summary
Skin aging is a multifactorial process involving the 3 layers of the skin: Epidermis, dermis and hypodermis. Skin aging process involves among others: skin roughness (epidermis), skin dyschromia (epidermis, dermis), wrinkles and elastosis - skin texture changes due to collagen modification, skin laxity and cellulite (dermis and hypodermis). EndyMion has developed the Imagine™ system - Computerized Radiofrequency System for Skin Tightening. By using a multielectrodes treatment tip an exact computerized thermal pattern can be produced allowing to selectively heating one or more of the target tissues (epidermis, dermis and hypodermis). In the skin tightening module the dermis and hypodermis would be targeted, creating enough thermal effect to induce collagen remodeling with no ablative thermal damage in the epidermis or dermis. This post marketing study is intended for evaluation of safety and efficacy of the Imagine™ system.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jul 2008
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2009
CompletedFirst Submitted
Initial submission to the registry
July 23, 2009
CompletedFirst Posted
Study publicly available on registry
July 24, 2009
CompletedJuly 24, 2009
July 1, 2009
11 months
July 23, 2009
July 23, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The safety of using the Imagine™ System for skin tightening will be established by physician's assessment/observation of adverse events (signs of pain, skin texture alterations or burn).
3 months
Secondary Outcomes (1)
Efficacy endpoint of using the Imagine™ System for skin tightening will be established by level of skin tightness improvement.
3 months
Study Arms (1)
Endymion study group
EXPERIMENTALInterventions
Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed): * Pulse energy (J); * RF frequency (1MHz); * Pulse duration (30 sec); * Treatment hand piece (skin tightening);
Eligibility Criteria
You may qualify if:
- Healthy males and females age 30 and up
- Subjects with Fitzpatrick 4 to 9 degrees of elastosis
- Subject able to comprehend and give informed consent for participation in this study
- Subject must commit to all treatments and follow-up visits
- Subject must sign the Informed Consent Form
You may not qualify if:
- Subjects with implanted pacemakers, arrhythmias or any other severe known heart disorder
- Subjects with any implantable metal device in the treatment area
- Subjects on any medication that would affect the characteristic of the skin (medical or hormonal), such as "Accutane", within the past 6 months
- Subjects that have had any other invasive or non invasive method of skin therapy or hair removal performed in the past 6 months (in the treated area)
- Subjects who are scheduled or planned for any other invasive or non invasive method of skin therapy or hair removal in the treatment area at the period of the study
- Subjects who have any form of suspicious lesion on the treatment area
- Subjects with history of keloid formations or hypertrophic scarring
- Pregnant or lactating Subjects
- Subjects with Epilepsy or severe migraines
- Subjects with permanent makeup/ tattoo/ body piercing (in the treated area)
- Subjects with any Infection / abscess / pains in treatment target area
- Eczema or dermatitis
- Subjects who suffer from autoimmune disorders or diabetes
- Subjects using blood thinning medications
- Subjects with clotting disorders
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Elman Clinique
Rishon LeZiyyon, Israel
Study Officials
- STUDY DIRECTOR
Varda Godfried, Dr.
Endymion Medical Ltd
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
July 23, 2009
First Posted
July 24, 2009
Study Start
July 1, 2008
Primary Completion
June 1, 2009
Study Completion
July 1, 2009
Last Updated
July 24, 2009
Record last verified: 2009-07